Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2011, Vol. 16 ›› Issue (9): 1030-1032.

Previous Articles     Next Articles

Comparison of clinic efficacy between 99Tc-MDP and alendronate in patients with senile osteoporosis

PAN Wei-min, WANG Shen-jian, YAN Wei-wen, XIE Quan, ZHOU Ying, WANG Chao-qun   

  1. Department of Nuclear Medicine, Hainan Medical University, Haikou 570102, Hainan, China
  • Received:2011-08-27 Revised:2011-09-10 Online:2011-09-26 Published:2011-10-11

Abstract: AIM: To compare the clinical efficacy and safety of 99Tc-MDP and alendronate therapy on senile osteoporosis. METHODS: Adult patients (n=80) with senile osteoporosis were randomized into Group alendronate (n=40)and Group 99Tc-MDP(n=40), all patients were given full dosage of calcium agent and vitamin D therapy. Group alendronate (n=40) were given alendronate; Group 99Tc-MDP(n=40) were given 99Tc-MDP.After treatment,the efficacy was evaluated by the digital analog score (VAS)of the pain and detecting bone mineral density(BMD). RESULTS: After treatment,the lumbodorsal pain scores were decreased in two groups.While the efficacy of odynolysis in Group 99Tc-MDP was faster and better than that in Group alendronate(P<0.05); the BMD of two groups were increased to some extent, the peak clinical efficacy appeared at six months in Group 99Tc-MDP(P<0.05). CONCLUSION: 99Tc-MDP decreases pain more quickly and obviously,and can also increase the BMD in patients with severe senile osteoporosis. Alendronate shows higher safety in long-term treatment of senile osteoporosis.

Key words: Senile osteoporosis, 99Tc-MDP, Alendronate

CLC Number: